{"result": "(\"entity\"<|>SPAIN<|>GEO<|>Spain is a country in Southwestern Europe, known for its diverse culture and history, and is relevant in the context of medical practices and guidelines.)\n##\n(\"entity\"<|>MÉXICO DF<|>GEO<|>Mexico City (México DF) is the capital of Mexico, where medical literature and guidelines may be published and referenced.)\n##\n(\"entity\"<|>DHEA-S<|>PERSON<|>DHEA-S (Dehydroepiandrosterone sulfate) is a hormone that is often measured in women to assess adrenal function and is relevant in the context of adrenal incidentalomas.)\n##\n(\"relationship\"<|>HARRISON PRINCIPIOS DE MEDICINA INTERNA<|>MÉXICO DF<|>Harrison Principios de Medicina Interna is published in Mexico DF, indicating its relevance to the medical community there<|>5)\n##\n(\"relationship\"<|>DHEA-S<|>ALDOSTERONA<|>DHEA-S and aldosterona are both hormones produced by the adrenal glands and are important in evaluating adrenal function<|>7)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ales. Las diferencias entre adenomas y carcinomas se basan en el diferente\n     terísticas radiológicas iniciales son equívocas y se decide realizar tratamiento conserva-                                              contenido de lípidos y en la diferente vascularización.\n     dor, sería aconsejable una prueba de imagen para valorar el crecimiento a corto plazo de\n     3-6 meses y posteriormente anual durante 2 años para comprobar estabilidad.                                                             El tratamiento quirúrgico está reservado para los nódulos que por su tamaño o crecimien-\n     El ratio aldosterona/actividad de renina plasmática (ALD/ARP) debe realizarse a primera                                                 to sean molestos o exista la sospecha de malignidad, y para los nódulos hiperfuncionantes.\n     hora de la mañana, con el paciente sentado. No precisa la retirada de la medicación antihi-                                             En principio está claro que los nódulos con tamaño superior a los 6 cm tienen indicación\n     pertensiva, con algunas salvedades. Los antagonistas de la aldosterona (espironolactona                                                 quirúrgica, ya que en alguna serie se               ha descrito que, entre estos, el 25% serán carcinomas\n     y eplerenona)       deben ser retirados 6 semanas antes para poder hacer una interpretación                                             y el 18%, metástasis.\n     correcta, excepto cuando persiste la hipopotasemia a pesar del tratamiento, lo que indica                                               Referencias:\n     que el receptor de aldosterona está completamente bloqueado y la actividad de renina plas-                                              • Arlt W. Trastornos de la corteza suprarrenal. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison\n                                                                                                                                               Principios de Medicina Interna. 19.ª edición en español. México DF: Mc Graw Hill; 2016. p. 2309-29.\n     mática sí que podría suprimirse en el paciente con hiperaldosteronismo primario, siendo                                                 • Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentaloma: European Society\n     esta la única situación en la que el ratio ALD/ARP sería útil.                                                                            of Endocrinology Clinical Practice. Guideline in collaboration with the European Network for the Study of adrenal tumors.\n                                                                                                                                               Eur J Endocrinol. 2016;175:G1-G34.\n     Referencias:                                                                                                                            • Recasens Sala M. Incidentaloma adrenal. Manual de Endocrinología y Nutrición. Disponible en: https://manual.seen.es\n                                                                                                                                               (última modificación: 25 de noviembre de 2015).\n     • Arlt W. Trastornos de la corteza suprarrenal. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison      • Steward PM, Newell-Price JDC. The adrenal cortex. En: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook\n       Principios de Medicina Interna. 19.ª edición en español. México DF: Mc Graw Hill; 2016. p. 2309-29.                                     of Endocrinology. 13.ª ed. Philadelphia.: Elsevier; 2016. p. 490-555.\n     • Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentaloma: European Society       • Young WF, Jr, Kebebew E. The adrenal incidentaloma. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Literature\n       of Endocrinology Clinical Practice. Guideline in collaboration with the European Network for the Study of adrenal tumors.               review current through: Apr. 2019.\n       Eur J Endocrinol. 2016;175:G1-G34.\n     • Recasens Sala M. Incidentaloma adrenal. Manual de Endocrinología y Nutrición. Disponible en: https://manual.seen.es\n       (última modificación: 25 de noviembre de 2015).\n     • Steward PM, Newell-Price JDC. The adrenal cortex. En: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook         Indique qué es verdad en los incidentalomas suprarrenales:\n       of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016. p. 490-555.                                                              37\n     • Young WF, Jr, Kebebew E. The adrenal incidentaloma. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com.\n       Literature review current through: Apr. 2019.                                                                                         A. Se sospecha malignidad cuando la radiodensidad es de más 10 unidades Hounsfield.\n                                                                                                                                             B. Únicamente se debe medir DHEA-S en mujeres.\n                                                                                                                                             C. Uno de cada cuatro incidentalomas mayores de 6 cm de diámetro son malignos.\n                                                                                                                                             D.  La adrenalectomía por laparoscopia está indic\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>HARRISON PRINCIPIOS DE MEDICINA INTERNA<|>ORGANIZATION<|>Harrison Principios de Medicina Interna is a medical textbook that provides comprehensive information on internal medicine, including adrenal disorders.)\n##\n(\"entity\"<|>EUROPEAN SOCIETY OF ENDOCRINOLOGY<|>ORGANIZATION<|>The European Society of Endocrinology is a professional organization that provides guidelines and research on endocrine disorders, including adrenal incidentalomas.)\n##\n(\"entity\"<|>UPTODATE<|>ORGANIZATION<|>UpToDate is a clinical decision support resource that provides evidence-based information on various medical topics, including adrenal incidentalomas.)\n##\n(\"entity\"<|>ADRENAL INCIDENTALOMA<|>EVENT<|>Adrenal incidentaloma refers to an adrenal mass discovered incidentally during imaging studies performed for other reasons, which may require further evaluation for malignancy.)\n##\n(\"entity\"<|>ALDOSTERONA<|>PERSON<|>Aldosterona is a hormone produced by the adrenal glands that helps regulate blood pressure and fluid balance, often discussed in the context of adrenal disorders.)\n##\n(\"entity\"<|>RENINA PLASMÁTICA<|>PERSON<|>Renina plasmática is an enzyme secreted by the kidneys that plays a crucial role in blood pressure regulation and is often measured in conjunction with aldosterone levels.)\n##\n(\"relationship\"<|>HARRISON PRINCIPIOS DE MEDICINA INTERNA<|>EUROPEAN SOCIETY OF ENDOCRINOLOGY<|>Harrison Principios de Medicina Interna references guidelines from the European Society of Endocrinology regarding adrenal incidentalomas<|>7)\n##\n(\"relationship\"<|>EUROPEAN SOCIETY OF ENDOCRINOLOGY<|>UPTODATE<|>The European Society of Endocrinology provides guidelines that may be referenced in UpToDate for clinical decision-making regarding adrenal incidentalomas<|>6)\n##\n(\"relationship\"<|>ADRENAL INCIDENTALOMA<|>HARRISON PRINCIPIOS DE MEDICINA INTERNA<|>Harrison Principios de Medicina Interna discusses the management and implications of adrenal incidentalomas<|>8)\n##\n(\"relationship\"<|>ALDOSTERONA<|>RENINA PLASMÁTICA<|>Aldosterona and renina plasmática are both involved in the regulation of blood pressure and are often measured together in patients with adrenal disorders<|>9)\n<|COMPLETE|>"}]}